Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | BCL11B |
| Gene Name: | BCL11B |
| Protein Full Name: | B-cell lymphoma/leukemia 11B |
| Alias: | BC11B; B-cell CLL/lymphoma 11B; B-cell CLL/lymphoma 11B (CTIP2); B-cell CLL/lymphoma 11B (zinc finger protein); B-cell lymphoma/leukaemia 11B; BCL11B; COUP-TF-interacting protein 2; CTIP2; CTIP-2; Radiation-induced tumor suppressor gene 1; RIT1; Zinc finger protein hRit1 alpha |
| Mass (Da): | 95519 |
| Number AA: | 894 |
| UniProt ID: | Q9C0K0 |
| Locus ID: | 64919 |
| COSMIC ID: | BCL11B |
| Gene location on chromosome: | 14q32.2 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 20588 |
| Percent of cancer specimens with mutations: | 1.08 |
| Deregulated in translocations: | T-cell acute lymphoblastic leukemia, pediatric (15-20%), adult (100%). Fusion partner TLX3. |
| Normal role description: | BCL11B is transcriptional repressor localized to the inner nuclear membrane. BCL11B may have a role in T-cell development. A known fusion partner of TLX3, TLX3-BCL11B fusions are implicated in 15-20% of all pediatric and 100% of adult T-cell acute lymphoblastic leukemia. BCL11B may also have a role in mediating p53 signalling and through repression of cell growth promoting genes may act as a tumour suppressor. |